MedTrace Logo

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

NCT01121133 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-11-21

No results posted yet for this study

Summary

This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.

Conditions

  • Lymphoma, Including Chronic Lymphocytic Leukemia
  • Solid Tumors

Interventions

DRUG

navitoclax

Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.

DRUG

Rifampin

Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-05-31
Completion
2011-05-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01121133 on ClinicalTrials.gov